ARCHIVES

DCT Board Committee Drawing Up Plans On How To Spend Biological Response Modifiers Money

This article is from The Cancer Letter archive.

Vol. 05 No. 35 | August 31, 1979

Download PDF Visit The Full Archive

Related Articles

Aggressive, Tailored Therapy Improves Survival, Study Finds

October 31, 2008

FDA Requires Independent Confirmation of Disease Progression in Cooperative Group Trials; Seeks Documentation for Avastin in Breast Cancer.

September 15, 2006

Cancer Support Community Reports on Patient Experiences

October 24, 2014

Cancer Vaccine RFAs Approved In Concept By NCI Advisors

July 26, 1991

Afatinib Delays Tumor Growth In LUX-Head and Neck 1 Study

October 31, 2014

Somatuline Demonstrates 65.1 Percent Of Patients Progression-Free at 96 Weeks

July 25, 2014